Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Stock data | 2023 | Change |
---|---|---|
Price | $135.75 | N/A |
Market Cap | $29.24B | N/A |
Shares Outstanding | 215.40M | 1.36% |
Employees | 15.69K | N/A |
Shareholder Equity | 17.30B | 108.62% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 6.11 | N/A |
P/S Ratio | 8.01 | N/A |
P/B Ratio | 1.69 | N/A |
P/FCF | 65.75 | N/A |
Dividends | 2023 | Change |
---|---|---|
Dividend Yield | 2.16% | N/A |
Dividend per share | 2.9373 | N/A |
Dividend Payout Ratio | 0.8879 | N/A |
Growth | 2023 | Change |
---|---|---|
ROIC | 0.1640 | N/A |
CAPEX | -150.76M | N/A |
Return on Equity | 0.0412 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $3.65B | N/A |
Earnings | $712.55M | N/A |
Free Cash Flow | $444.69M | N/A |
EPS | 22.20 | N/A |
Earnings Yield | 0.1635 | N/A |
Gross Margin | 0.6664 | N/A |
Operating Margin | 0.2794 | N/A |
Net income margin | 0.1952 | N/A |
FCF Margin | 0.1218 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $7.17B | N/A |
Total Debt | $2.92B | N/A |
Cash on Hand | $135.72M | N/A |
Debt to Equity | 0.2658 | -49.26% |
Cash to Debt | 0.0466 | 37.60% |
Current Ratio | 0.6092 | -49.05% |
Other data | 2023 | Change |
---|---|---|
Buyback Yield | 0.0000 | N/A |